Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025
Company Deals

Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics

Fineline Cube Dec 29, 2025
Company Deals

Hybio Pharmaceutical, Dr. Reddy’s Forge Peptide API Partnership

Fineline Cube Dec 29, 2025
Company Deals

Shionogi Acquires RADICAVA ALS Business for $2.5 Billion from Tanabe Pharma

Fineline Cube Dec 23, 2025
Company Deals

Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal

Fineline Cube Dec 23, 2025
Company Policy / Regulatory

NDRC Expands Foreign Investment in Healthcare with 2025 Catalogue

Fineline Cube Dec 29, 2025
Company Drug

Sino Biopharmaceutical’s TQH3906 Achieves 90% PASI 75 Response in Phase 2 Psoriasis Trial

Fineline Cube Dec 29, 2025
Company Drug

AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy

Fineline Cube Dec 29, 2025
Company

Three Senior Executives of Henan Topfond Pharmaceutical Under Investigation

Fineline Cube Nov 24, 2024

On November 22, China General Technology (Group) Holding released three official announcements through its official...

Company

Leman Biotech Enters Zhongshan Life Science Park to Accelerate CAR-T Innovation

Fineline Cube Nov 24, 2024

Innovative biotechnology company Leman Biotech, focused on cutting-edge cell therapy technology, has announced its official...

Company

BRL Medicine Inc. Secures Nearly $30 Million in B+ Round Financing to Advance Pipeline

Fineline Cube Nov 23, 2024

On November 22, 2024, BRL Medicine Inc. announced the completion of nearly 200 million yuan...

Company

Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies

Fineline Cube Nov 23, 2024

On November 22, 2024, B&K Corporation Limited (Bio-Bank Corp.), a biopharmaceutical company headquartered in China,...

Company Drug

HutchMed Anticipates Milestone Payment as Takeda Launches Fruzaqla in Japan for CRC

Fineline Cube Nov 22, 2024

China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) is poised to receive a milestone payment...

Company Drug

First Patient Dosed in Abbisko’s Phase II Trial of ABSK061 and ABSK043 in FGFR2/3 Altered Tumors

Fineline Cube Nov 22, 2024

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the first patient dosing in...

Company Drug

Bayer’s Nubeqa Files for FDA Approval in mHSPC

Fineline Cube Nov 22, 2024

German pharmaceutical company Bayer AG (ETR: BAYN) has announced that the US Food and Drug...

Company

MSD China to Streamline Diabetes Business Amid Volume-Based Procurement Inclusion

Fineline Cube Nov 22, 2024

The China unit of US pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK)...

Company Deals

Zai Lab Ltd Partners with Pfizer for Commercialization of Xacduro in China

Fineline Cube Nov 22, 2024

China-based biotechnology company Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced a strategic collaboration...

Company Drug

China Grants Marketing Approval for MSD’s Welireg for von Hippel-Lindau Disease Tumors

Fineline Cube Nov 22, 2024

China’s National Medical Products Administration has issued marketing approval for Merck, Sharp & Dohme’s (MSD;...

Company

Medtronic Reports 5% Organic Revenue Growth in Q2 FY25 with Strong Portfolio Performance

Fineline Cube Nov 22, 2024

US-Irish medical device company Medtronic (NYSE: MDT) has announced its financial results for the second...

Company Deals

Pfizer and Flagship Pioneering Expand Partnership with Two New Biotechnology Agreements

Fineline Cube Nov 22, 2024

The billion-dollar, multi-program partnership between US pharmaceutical giant Pfizer (NYSE: PFE) and bioplatform innovation company...

Company Drug

Easton Pharmaceutical Secures NMPA Approval for Generic Jakavi and Urocit-K

Fineline Cube Nov 22, 2024

Chengdu-based Easton Pharmaceutical Co., Ltd (SHA: 688513) has announced that it has received separate marketing...

Company Drug

Innorna’s mRNA Drug IN015 Earns Orphan Drug Designation for PFIC Treatment

Fineline Cube Nov 22, 2024

Shenzhen-based Innorna Co., Ltd, a leading platform company specializing in mRNA technology and LNP (lipid...

Company Deals

Kura Oncology and Kyowa Kirin Ink Licensing Deal for Menin Inhibitor Ziftomenib

Fineline Cube Nov 22, 2024

US-based Kura Oncology, Inc. (NASDAQ: KURA) has entered into a licensing deal with Japan-headquartered Kyowa...

Company Drug

Jiangsu Hengrui Receives NMPA Approval for HRS-6208 Solid Tumor Clinical Study

Fineline Cube Nov 22, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from...

Company Deals

CR Pharma’s CR Sanjiu to Sell 51% Stake in Shenghuo for RMB 1.791 Billion

Fineline Cube Nov 22, 2024

China Resources Pharmaceutical Group Co., Ltd (HKG: 3320) has announced a significant internal restructuring within...

Company Drug

InxMed’s Ifebemtinib Earns Breakthrough Therapy Designation for NSCLC Treatment in China

Fineline Cube Nov 22, 2024

China-based InxMed (Nanjing) Co., Ltd has announced that the Center for Drug Evaluation of the...

Company Deals

Novartis Expands Gene Therapy Portfolio with Acquisition of Kate Therapeutics

Fineline Cube Nov 22, 2024

Swiss pharmaceutical company Novartis (NYSE: NVS) has announced the acquisition of US-based Kate Therapeutics, Inc.,...

Company Deals Drug

Hua Medicine and Bayer AG Terminate Co-promotion Agreement for HuaTangNing

Fineline Cube Nov 22, 2024

China-based Hua Medicine (HKG: 2552) has announced the termination of its co-promotion agreement with German...

Posts pagination

1 … 197 198 199 … 602

Recent updates

  • Sino Biopharmaceutical’s TQH3906 Achieves 90% PASI 75 Response in Phase 2 Psoriasis Trial
  • HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology
  • Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics
  • AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy
  • AstraZeneca Secures NMPA Approval for Fasenra in EGPA, Demonstrating Superior Steroid-Sparing Effect
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sino Biopharmaceutical’s TQH3906 Achieves 90% PASI 75 Response in Phase 2 Psoriasis Trial

Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Company Deals

Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics

Company Drug

AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.